These findings imply that more than half of all EGFRm+ NSCLC tumors are likely to harbor an extremely low proportion (<0.1%) of T790M mutations even before EGFR‐TKI treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.